241 related articles for article (PubMed ID: 38245636)
1. Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
Zhu L; Qin J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):22. PubMed ID: 38245636
[TBL] [Abstract][Full Text] [Related]
2. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Lorenzi M; Resi MV; Bonanno L; Frega S; Dal Maso A; Ferro A; Guarneri V; Pasello G
Front Immunol; 2024; 15():1308109. PubMed ID: 38348046
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
6. What Are the Biomarkers for Immunotherapy in SCLC?
Longo V; Catino A; Montrone M; Pizzutilo P; Annese T; Pesola F; Marech I; Cassiano S; Ribatti D; Galetta D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681779
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for small cell lung cancer: established applications and novel approaches.
Scott SC; Hann CL
Clin Adv Hematol Oncol; 2021 Oct; 19(10):654-663. PubMed ID: 34637432
[TBL] [Abstract][Full Text] [Related]
8. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Tian Y; Zhai X; Han A; Zhu H; Yu J
J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
Wang L; Lei X; Wang X
Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.
Caliman E; Fancelli S; Petroni G; Gatta Michelet MR; Cosso F; Ottanelli C; Mazzoni F; Voltolini L; Pillozzi S; Antonuzzo L
Lung Cancer; 2023 Jan; 175():88-100. PubMed ID: 36493578
[TBL] [Abstract][Full Text] [Related]
11. Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?
Fasano R; Serratì S; Rafaschieri T; Longo V; Di Fonte R; Porcelli L; Azzariti A
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672414
[TBL] [Abstract][Full Text] [Related]
12. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy Advances in Small Cell Lung Cancer].
Xu Y; Zhan P; Song Y
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
15. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis.
Chen CY; Chen WC; Hung CM; Wei YF
Immunotherapy; 2021 Oct; 13(14):1165-1177. PubMed ID: 34261336
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
18. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
Tian Y; Ma J; Jing X; Zhai X; Li Y; Guo Z; Yu J; Zhu H
Cancer Lett; 2022 Aug; 541():215719. PubMed ID: 35597478
[TBL] [Abstract][Full Text] [Related]
20. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer.
Lim JU; Kang HS
Ann Transl Med; 2021 May; 9(9):809. PubMed ID: 34268422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]